A. Jurdi

Natera (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

S. Sharma

Natera (United States)

M.C. Liu

Natera (United States)

G. Laliotis

Natera (United States)

V. Aushev

Ichiro Takemasa

Sapporo Medical University

K. Yamazaki

Shizuoka Cancer Center

K. Mori

Shizuoka Cancer Center

S. Kopetz

The University of Texas MD Anderson Cancer Center

P.M. Kasi

Weill Cornell Medicine

M. Ikeda

Hyogo University

Cooperative Institutions

Istituti di Ricovero e Cura a Carattere Scientifico

National Cancer Center Hospital East

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

University of Washington

University of Washington Medical Center

Natera (United States)

Fred Hutch Cancer Center

The University of Texas MD Anderson Cancer Center

Methodist Hospital

Cancer Research Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

499TiP A single arm phase II trial of trastuzumab deruxtecan in patients with gastro-oesophageal adenocarcinoma cancer who are ctDNA and HER2 positive: DECIPHER (TRIALS IN PROGRESS)

Annals of Oncology (2024)

Elizabeth Smyth Daniel E. Griffiths Kelly Cozens Chris Hurt Robert Waugh

DECIPHER

10.1016/j.annonc.2024.05.411

Cite

Citations (0)

274P Utility of MRI-based radiomic metrics and circulating tumor DNA to predict outcomes in locally advanced rectal cancer

Annals of Oncology (2024)

Giorgia Marisi Chiara Molinari Giacomo Feliciani Andrea Iamurri Prochowski G. Laliotis

Circulating tumor DNA

10.1016/j.annonc.2024.05.280

Cite

Citations (0)

114P Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers

Annals of Oncology (2023)

Gentry Teng King Stacey A. Cohen E. Gabriela Chiorean William Proctor Harris Raymond S. Yeung

Adjuvant Therapy

Circulating tumor DNA

10.1016/j.annonc.2023.09.1407

Cite

Citations (3)

Circulating tumor DNA monitoring for recurrence detection and treatment response assessment in HCC

HPB (2024)

Maen Abdelrahim Abdullah Esmail Aiwu Ruth He Durham Victor S. Kodali

Circulating tumor DNA

10.1016/j.hpb.2024.04.025

Cite

Citations (0)

553P Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY

Annals of Oncology (2024)

Jason M. Nagata Yuichi Nakamura Junichiro Watanabe Naoya Akazawa M. Ikeda

10.1016/j.annonc.2024.08.622

Cite

Citations (0)

90P Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma

Annals of Oncology (2022)

G. Azzi M. Tavallai V. Aushev A.E. Koyen Malashevich G. Botta

Circulating tumor DNA

Dna testing

10.1016/j.annonc.2022.10.126

Cite

Citations (0)

558P Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY

Annals of Oncology (2024)

Kozo Kataoka K. Mori Yoshitsugu Nakamura Junichiro Watanabe Ken‐ichi Hirata

Adjuvant Chemotherapy

Subgroup analysis

10.1016/j.annonc.2024.08.627

Cite

Citations (0)

161TiP A phase II study of mFOLFOXIRI after metastasectomy in patients with oligometastatic colorectal cancer (FANTASTIC study)

Annals of Oncology (2024)

M. Ikeda Kozo Kataoka Takaaki Yamada K. Yamazaki K. Mori

Metastasectomy

10.1016/j.annonc.2024.05.171

Cite

Citations (1)

4MO Is it time for a new staging system for colon adenocarcinoma (CA)?

Annals of Oncology (2024)

N.A. Dasari A. Jurdi Y. Nakamura V. Aushev Pashtoon Murtaza Kasi

Colon adenocarcinoma

Colorectal adenocarcinoma

10.1016/j.annonc.2024.05.015

Cite

Citations (0)

319MO Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer

Annals of Oncology (2022)

S.A. Cohen P.M. Kasi V.N. Aushev D.L. Hanna G.P. Botta

Cancer recurrence

Circulating tumor DNA

10.1016/j.annonc.2022.07.457

Cite

Citations (2)